Ascendis Pharma Oncology Division A/S
Clinical trials sponsored by Ascendis Pharma Oncology Division A/S, explained in plain language.
Ascendis Pharma Oncology Division A/S
ASND
NASDAQ
Biopharmaceutical company focused on oncology therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New immune drug shows promise in early trial for Hard-to-Treat cancers Results expected Aug 2027 (estimated)